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Rheumatoid arthritisAbstract Background: Methotrexate (MTX) and anti-malarial drugs are widely prescribed for
rheumatoid arthritis (RA) as disease-modifying anti-rheumatic drugs (DMARDs). Some patients
discontinue treatment because of their adverse effects which could induce disease reactivation.
Aim of the work: We aimed to evaluate common causes of DMARD discontinuation such as
MTX, chloroquine (CQ) and hydroxychloroquine (HCQ) in patients with rheumatoid arthritis.
Patients and methods: We reviewed the records of RA patients referred to the rheumatologic
clinic of Shariati Hospital in 2006 and their records were retrospectively reviewed till 1991. Patients
who received MTX (with or without CQ or HCQ consumption) for at least one month were
included to determine the frequency and more prevalent causes of drug discontinuation.
Results: Among 295 RA patients, 28.5% discontinued MTX. Adverse drug effects were found in
27.4% of the patients. However, no serious adverse events such as cirrhosis were reported. Among
271 patients who received antimalarial agents, 41.3% discontinued treatment. 51.3% of drug with-
drawals were because of ophthalmological consultation and presence of retinopathy, macular pig-
mentation, and keratopathy, without any persistent or serious ocular complication such as
blindness. Only patients who discontinued treatment due to retinopathy were signiﬁcantly older
than the others.
Conclusion: With respect to the relatively low rate of discontinuation due to adverse effects,
MTX seems to be a safe drug for long-term use in RA patients. Serial eye examination for those
using antimalarial drug will protect them against ocular toxicity which could further lead to higher
rates of drug discontinuation.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is the most common form of
chronic inﬂammatory arthritis [1]. It is a multi-factorial disease
148 B. Anvarisustained by environmental and genetic factors with substan-
tial evidence implicating cytokines in its pathogenesis and
determining the effectiveness of RA treatment with methotrex-
ate (MTX) and glucocorticoids [2]. With respect to the wide-
spread prescription of disease-modifying anti-rheumatic
drugs (DMARDs) in RA patients [3], more attention should
be paid to adverse drug effects, especially those that lead to
drug discontinuation. This could prevent any harm to the
patients and facilitate the establishment of better practical
guideline for routine medical practice [4]. Also sudden
DMARD withdrawal may precipitate disease reactivation [5].
A considerable relation was reported between the MTX dose
and disease activity in RA patients [6]. Common DMARDs
prescribed for RA include MTX [7] and antimalarial agents
such as chloroquine (CQ) or hydroxychloroquine (HCQ) [8].
MTX is a safe, effective and useful therapy for RA. An aspect
of the evolving optimism in RA treatment has been the use of
multiple agents in combination therapy [9]. Many patients stop
medications because of their physicians’ order, while others
discontinue medication because of experiencing unwanted
adverse effects [8].
In a retrospective multicenter study of 760 RA patients that
analyzed reasons for DMARD discontinuation, 47.1%, 43.2%
and 9% interrupted therapy due to lack of efﬁcacy, adverse
events, or undeﬁned reasons, respectively [10]. The most serious
toxicities of MTX include hepatic ﬁbrosis, cirrhosis, pneumoni-
tis and myelosuppression which require serial monitoring of the
complete blood cells count (CBC), aspartate aminotransferase
(AST), albumin and creatinine every 4–8 weeks [11]. Antimalar-
ials require intensive monitoring to avoid severe retinal damage
that can lead to blindness. Appropriate examinations should be
performed regularly in order to decide whether to taper or stop
when damage is still mild, preclinical or reversible [12]. A ran-
domized clinical trial showed that adverse effects of HCQ led to
permanent discontinuation in 10 of 120 patients due to gas-
trointestinal complaints in 5, mucocutaneous problems in 4
and disturbed vision in 1 patient [13].
Some researchers emphasize that follow-up eye examina-
tions should be performed with 6–12 months intervals [14,15]
while others suggest routine ophthalmic screening is not neces-
sary in patients whose renal function is normal, if the daily
dosage is <6.5 mg/kg [16]. A multicenter study on 1162
patients to evaluate the causes of DMARD discontinuation
showed that antimalarial agents were the second most frequent
DMARDs to be discontinued [17].
We aimed to evaluate the common causes for discontinua-
tion of methotrexate, chloroquine, and hydroxychloroquine in
a cohort of Iranian RA patients. Possible risk factors and irre-
versible outcome of adverse effects were also studied in rela-
tion to drug discontinuation.2. Patients and methods
In this retrospective study, 295 patients with RA who received
P7.5 mg MTX weekly for at least one month and who had
been referred to the Rheumatology Clinic of Shariati Hospital
in 2006, Tehran, Iran were included. All the patients included
fulﬁlled the 1987 revised American Rheumatism Association
criteria for classiﬁcation of RA [18]. Ethics committee of Teh-
ran University of Medical Science approved the study proposal
and all of data were gathered in numbered coding system toobscure patient‘s name. Samples were collected among
patients who were visited at the Clinic in 2006 and their
records were retrospectively reviewed reaching back to 1991.
All of the patients had serial follow-up and serial laboratory
ﬁndings were documented.
These records were reviewed for ﬁnding any evidence of
MTX prescription and those who received it for at least one
month were included. Simultaneously their charts were
reviewed for CQ or HCQ prescription and any discontinuation
(temporary or permanent discontinuation until data gathering
time in 2006) were noted. Finally, the patients were divided
into two groups: those who discontinued the drugs and those
who continued them (for each drug group). MTX dose was
calculated as mean dose per month instead of weekly dosage
because of the better presentation of changing dosage in the
previous visit [19].
Our data collection form consisted of items regarding the
patients’ characteristics: age, sex, body mass index (BMI), dis-
ease activity, dosage and duration of prednisolone consump-
tion and any concurrent DMARD consumption as CQ or
HCQ; their dosages and duration and weekly MTX; dose,
duration and cumulative dose. The results of serial laboratory
tests at each visit were also recorded such as: CBC, blood urea
nitrogen (BUN), creatinine, creatinine clearance (CrCl) calcu-
lated by Cockroft-Gault equation [20], AST, alanine amino-
transferase (ALT), alkaline phosphatase (ALP), serum
albumin, prothrombin time and bilirubin as well as liver sonog-
raphy (if available). Biannual ophthalmological consultations
were obtained from the patients’ records for those who used
CQ or HCQ to evaluate ocular complications leading to drug
discontinuation. Any cause of drug discontinuation was identi-
ﬁed based on the records and was added. Finally, initiation of
the same drug (compared with persistent drug discontinuation)
was noted and their following laboratory ﬁndings were col-
lected to evaluate other adverse drug reactions.
2.1. Statistical analysis
Data were analyzed using SPSS software, version 12. The data
were summarized using descriptive statistics: mean ± standard
deviation (±SD), or frequencies (number) and percentages
(%). T-test and Chi-square test were used as appropriated. A
probability value p< 0.05 was considered statistically
signiﬁcant.
3. Results
Among the 295 patients with RA who received MTX, 271
(91.9%) also used CQ or HCQ during their follow-up course
at the clinic during the study period. The age of the patients
was 49.4 ± 12.8 years and 84.4% were women. Their CrCl
was 105.2 ± 36.6 cc/min/1.73 m2 and no evidence of severe
renal insufﬁciency (CrCl < 30 cc/min/1.73 m2) was observed.
The mean duration of MTX treatment was 40.5
± 34.6 months and the mean dose was 35.7 ± 11.4 mg/month.
Body mass index, disease activity and laboratory features of
the RA patients are presented in Table 1.
Eighty-four (28.5%) patients discontinued MTX temporar-
ily but only 23 (7.8%) discontinued it permanently. None of
them developed severe or irreversible clinical or laboratory
complication such as cirrhosis or pulmonary ﬁbrosis. In most
Table 1 Body mass index, disease activity and laboratory
features of RA patients receiving MTX and anti-malarials.
Parameter mean ± SD
or n/total n (%)
RA patients (n= 295) receiving
MTX (n= 295) CQ/HCQ (n= 271)
BMI (kg/m2) 27.3 ± 4.7 27.3 ± 4.8
Active RA 94/295 (31.9) 85/271 (31.4)
BUN (mg/dl) 18.9 ± 0.1 18.7 ± 5.6
Serum creatinine (mg/dl) 0.8 ± 0.1 0.8 ± 0.1
Decreased cell count* 13/294 (4.4) 12/270 (4.4)
Elevated ALT 82/293 (28) 81/269 (30.1)
Elevated AST 62/293 (21.2) 55/269 (20.5)
Elevated ALP 19/102 (18.6) 18/93 (19.4)
Decreased albumin 1/27 (3.7) 1/25 (4)
Elevated bilirubin 2/48 (4.2) 1/46 (2.2)
Increased PT 1/25 (4) 1/24 (4.2)
RA: Rheumatoid arthritis, MTX: methotrexate, CQ: chloroquine,
HCQ: hydroxychloroquine, BMI: body mass index, BUN: blood
urea nitrogen, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, ALP: alkaline phosphatase, PT: prothrombin
time.
* Decreased cell count was deﬁned as WBC< 4000/ll or plate-
let < 100,000/ll.
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recorded (36.9%). Reported causes for MTX discontinuation
were as follows: controlled disease and the physician’s order
(26.2%), abnormal liver function test (11.9%), pregnancy
(8.3%), nausea and vomiting (5.9%), neutropenia or pancy-
topenia (3.6%), dyspnea due to suspected pulmonary adverse
drug effect in one patient, and blurred vision, epigastric pain,
urticaria and unknown hyper sensitivity (each seen in one
patient). Also one patient discontinued MTX because of
replacing with gold therapy. Overall, these adverse events were
seen in 27.4% of the patients who discontinued MTX (Table 2)
and abnormal liver function test was the most common
adverse effect. No liver biopsy was performed among these
patients.
Sonography reports were found among only ten patients
that showed fatty liver by 30%. Multiple stones despite ofTable 2 Causes of discontinuation of methotrexate (MTX)
and anti-malarials in rheumatoid arthritis (RA) patients
(n= 295).
n (%) RA patients (n= 295) receiving
MTX (n= 295) CQ/HCQ (n= 271)
Continued 211 (71.5) 154 (56.8)
Discontinued 84 (28.5) 117 (43.2)
Causes of discontinuation
Non-recorded cause 31 (36.9) 22 (18.8)
Remission 22 (26.2) 22 (18.8)
Adverse eﬀects 23 (27.4) 67 (57.3)
Pregnancy 7 (8.3) 6 (5.1)
Shift to gold therapy 1 (1.2) –
RA: rheumatoid arthritis, MTX: methotrexate, CQ: chloroquine,
HCQ: hydroxychloroquine.normal common bile duct in addition to fatty liver were
detected in one patient. Another patient with elevated liver
enzyme showed congestive hepatomegaly (due to CHF and
mitral stenosis). This patient had recurrent elevation of ALP
with normal gamma glutamyl transferase level from a few
years prior to MTX treatment. In another patient who had
two abnormal liver enzymes, nothing was found in the sonog-
raphy except for a liver hemangioma. Other 5 reports were
normal. Two of these patients had temporary discontinuation
of MTX. One of them had fatty liver disease and the other
congestive hepatomegaly. None of them discontinued MTX
permanently.
There was no signiﬁcant difference in age, sex, CrCl, and
duration of treatment with MTX between patients who discon-
tinued MTX and those who did not (Table 3). However, the
mean MTX dose per month among patients who discontinued
MTX was signiﬁcantly lower than those who did not (33.3
± 9.7 versus 36.6 ± 11.8 mg/month, p= 0.02). Antimalarials
(CQ/HCQ) were consumed for 4.6 ± 3.9 years by the patients
at a dosage of 150 and 200–400 mg daily, respectively.
Of the 271 patients who received antimalarials, 117 (43.1%)
discontinued treatment during their follow-up course and per-
manent discontinuation was seen in 102 (37.8%) patients.
Therefore, its discontinuation frequency was higher than
MTX; however duration of treatment with antimalarial drugs
was signiﬁcantly longer than MTX (p< 0.0001). After adjust-
ing the treatment duration, 61.8% of the patients who were
treated with antimalarial agents for less than 3.5 years contin-
ued to take it, compared to 69.9% of those being treated with
MTX per se (p= 0.38). No reason for CQ/HCQ discontinua-
tion was recorded in 22 (18.8%) patients. Sixty-seven (57.3%)
patients discontinued CQ/HCQ because of ocular adverse
effects based on ophthalmological consultation; 55 (91.6%)
of these patients stopped treatment permanently. These com-
plications were deﬁned as retinopathy, macular pigmentation
and keratopathy but none of them developed blindness or irre-
versible adverse outcome. After oculopathy, the second most
frequent cause for discontinuation was due to the physician’s
order because of controlled disease or changing CQ/HCQ to
another DMARD (18.8%) followed by pregnancy (5.1%).
Tinnitus, myopathy, unknown hypersensitivity and oral intol-
erance were among the other reasons for discontinuation, each
seen in one patient. Similar to MTX, no signiﬁcant difference
was found in age, sex, CrCl and duration of treatment with
antimalarials between patients who stopped drug consumption
and those who did not (Table 3). Retinopathy was comparable
between patients whose treatment duration was >3.5 years
(24.3%) and those <3.5 years (31.4%, p= 0.28). Only
patients who interrupted treatment due to retinopathy were
signiﬁcantly older than the others (53.9 ± 12.2 years versus
48.1 ± 12.6 years, p= 0.003).
4. Discussion
In this study, permanent discontinuation of MTX and anti-
malarial drugs was seen among 7.8% and 37.6% of the
patients, respectively. Adverse effects were seen in 27.4% of
patients who discontinued MTX and abnormal liver function
tests were the dominant reasons. Despite observing no serious
adverse outcome using CQ/HCQ, the frequency of drug dis-
continuation due to ocular toxicity was relatively high.
Table 3 Comparison between rheumatoid arthritis patients who continued and those who discontinued methotrexate and
antimalarial drugs.
Discontinuation Rheumatoid arthritis patients receiving
MTX (n= 295) CQ/HCQ (n= 271)
Yes No p Yes No p
84 (28.5) 211 (71.5) 117 (43.2) 154 (56.8)
Age (years) 50.1 ± 12.3 49.2 ± 13.1 0.6 50.6 ± 13.3 48.1 ± 12.6 0.3
Gender
Male 11(23.9) 35 (76.1) 0.3 16 (39) 25 (61) 0.3
Female 73 (29.3) 176 (70.7) 101(43.9) 129 (56.1)
CrCl 101.7 ± 32.2 106.6 ± 38.2 0.2 104.8 ± 33.6 107.1 ± 39.7 0.1
Treatment
Duration (m) 41.5 ± 33.5 40.1 ± 35.1 0.3 58.8 ± 45.6 52.8 ± 49.2 0.7
Dose
/month (mg) 33.3 ± 9.7 36.6 ± 11.8 0.02 –
Cumulative (g) 1.33 ± 1.1 1.36 ± 1.2 0.2 –
MTX: methotrexate, CQ: chloroquine, HCQ: hydroxychloroquine, CrCl: creatinine clearance, m: month. Data are presented as n (%) or mean
± SD. Bold values are signiﬁcant at p< 0.05.
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have been developed to reduce the risk of harm to the patients
[21]. Anti-malarial agents have relatively low rates of toxicity
[21,22]. Their most serious side effect is retinopathy which
could be prevented by adjusting drug dosage to the weight of
the patients. The recommended ‘‘safe” daily dose for HCQ is
6.5 mg/kg of body weight and 4 mg/kg for CQ [14]. All the
patients in our study adhered to this guideline which could
be the reason why no serious adverse outcome was reported.
The safety proﬁle of antimalarial drugs has been previously
reported [23,24]. The discontinuation rate in one study was
only 12.1% (due to unwanted effects) [8], which is much less
than ours. In another study [24], duration of treatment did
not predispose patients to toxicity, which is also supported
by our results. High frequency of drug discontinuation due
to ocular toxicity in our study may be attributed to close obser-
vation by serial annual eye examinations that detected earlier
stages of ocular toxicity and prevented serious outcomes such
as blindness.
A randomized clinical trial (RCT) of early RA reported
HCQ toxicity in 49.2% of the 120 studied patients, leading
to permanent discontinuation in 10 (8%) patients [13]. Five
patients developed diarrhea leading to permanent discontinua-
tion among two and dose reduction to 200 mg daily in the
other three. Other gastrointestinal complaints developed in
31 patients leading to discontinuation in two patients. Hydrox-
ychloroquine was also discontinued because of mucocutaneous
problems in 4 patients and due to disturbed vision in 1. The
mean treatment period was 59 weeks [13] that was shorter than
ours. The authors did not mention performing serial eye exam-
ination. Their common adverse effect, diarrhea, could be well
recognised in an RCT because of the prospective nature of
study, compared with the retrospective design of our study
which could reveal only well documented para clinical ﬁndings
such as abnormal liver function test, pancytopenia and also
ophthalmologic consultations in the patients‘ records. On the
other hand, with our retrospective study, we had access to
the patients’ long term follow-up which provided us with data
regarding the ﬁnal outcome of prolonged drug continuation.Many other factors such as performing routine laboratory
tests, their intervals or serial eye examinations could provide
clues to adverse drug effects. Some of these changes may be
mild and subclinical but could change the treatment course
and cause unnecessary drug corruption. Most causes for dis-
continuation in our study were the result of ﬁndings in serial
screenings. This may further inﬂuence the lower rate of severe
adverse outcome that all patients and also physicians are wor-
ried about.
Regarding MTX, previous studies reported discontinuation
rate due to adverse effect from 12.5% (among 273 Japanese
patients) [25] to 36.5% because of unwanted effects [8] and
56.5% in Americans [26]. One study demonstrated that
MTX is well tolerated on the long-term, so that over 50% of
patients starting MTX continued to take it 12 years later [27].
Another study on the reasons for MTX discontinuation [26]
showed adverse effects in 26 patients (56.5%), inefﬁcacy in 15
(32.6%), improvement of status in three (6.5%), pregnancy in
one (2.1%), and other diseases (lung cancer) in one (2.1%).
Those adverse effects consisted of gastrointestinal toxicity
(n= 6), oral ulcers, (n= 3), rash (n= 3), malaise (n= 3),
pulmonary symptoms (n= 3), pneumonia (n= 2), nodules
(n= 2), other side effects (n= 2), and abnormal laboratory
data in two patients (neither of which was found in routine
testing). So most common causes of discontinuation in the
mentioned study were clinical adverse effects compared with
our study in which the reason for discontinuation was undeter-
mined. If the undetermined causes were due to adverse effects,
their results will be near to ours. Another study showed that
toxic reactions leading to withdrawal were most common with
gold (62.6%) and MTX (62.5%) [10]. The lowest DMARDs’
discontinuation rate was reported in a Chinese population
[28]. In a retrospective multicenter study [10] to analyze rea-
sons for DMARD discontinuation, 47.1% of patients inter-
rupted therapy because of lack of efﬁcacy, 43.2% because of
adverse events, and 9% for undeﬁned reasons. The high rate
of MTX discontinuation because of undetermined cause in
our study may be due to poor record taking and limitations
due to the retrospective design of our study. An Egyptian
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of these patients stopped it due to gastric upset (nausea, gastri-
tis and peptic ulcer), one patient due to pneumonitis, one due
to leukopenia and two patients due to elevated liver enzymes
[29]. Based on frequent ﬁndings related to recurrent gastroin-
testinal complications among the mentioned articles, we may
be able to infer that one of the probable missing causes of dis-
continuation in our study could have also been gastrointestinal
adverse effects.
One study on 152 patients with RA treated with MTX
showed that the overall probability of continuing to take
MTX was 71.2% at 1 year, 55.5% at 3 years, 50% at 5 years,
and 49% at 6 years. After multivariate analysis, younger age
had no signiﬁcant effect on the probability of continuing
MTX therapy [30] that was compatible with our results. How-
ever, another study showed that increasing age is associated
with a greater tendency for MTX discontinuation in newly
diagnosed RA patients [31].
Based on our ﬁndings, there was no preference for older age
to develop MTX toxicity that elucidates close monitoring of all
patients irrespective of their age. In contrast, we found that
discontinuation of antimalarial drugs because of adverse
effects increased with age. Ultimately, different published data
from around the world could be summarized by a systematic
review to evaluate effective risk factors with respect to differ-
ent local confounding factors.
One of our important limitations was poor chart documen-
tation especially with respect to other patients‘ complaints (in
addition to musculoskeletal complaints and disease activity),
such as gastrointestinal complaints. Also, the retrospective
pattern of our study was another restriction.
In conclusion, with respect to the relatively low rate of drug
discontinuation due to adverse effects, MTX seems to be a safe
drug for long-term use in Iranian RA patients. Serial eye
examination for those using antimalarial drug will protect
them against ocular toxicity but it could lead to higher rates
of drug discontinuation. Regarding antimalarial dugs, most
of the causes for discontinuation were related to ocular com-
plaints detected by close observation and serial eye examina-
tion which could have had a preventive effect on serious
adverse outcomes previously reported.
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